Brought to you by 
Series C leads to $15mm for Entellus Medical
17 Jun 2008
Executive Summary
Entellus Medical (minimally invasive treatment for chronic sinusitis) brought in $15mm via a Series C financing led by first-time backer Montagu Newhall Associates, which was joined by returning shareholders Split Rock Partners and SV Life Sciences. The company will use the funds to launch its FinESS sinus technology later this year.
Deal Industry
- Medical Devices
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C leads to $15mm for Entellus Medical
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice